- Reuters•5 months ago
India's largest drugmaker Sun Pharmaceutical Industries expects its domestic consumer healthcare business to grow by up to 25 percent this year, led by a renewed marketing push on some older brands, the company's India chief said on Wednesday. The move is part of a wider thrust by the world's fifth-largest generic drugs company to expand its global consumer healthcare portfolio, which it has previously said it hopes to expand into a high-margin "growth engine". Sun Pharma plans to start selling some of its existing prescription dermatology products over the counter as part of the push, India Chief Executive Abhay Gandhi told reporters at a conference.
We're sorry this is all we were able to find about this topic.
GlaxoSmithKline Consumer Healthcare Limited (GSKCONS.NS)
NSE - NSE Delayed Price. Currency in INR
|Day's Range||5,961.00 - 6,110.55|
|52wk Range||5,405.00 - 6,800.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||36.25|
|Avg Vol (3m)||8,820|
|Dividend & Yield||N/A (N/A)|